Eikon Therapeutics to Join the Russell 3000® Index
Rhea-AI Summary
Eikon Therapeutics (Nasdaq:EIKN), a late-stage clinical biopharmaceutical company, will be added to the Russell 3000 Index following the annual reconstitution, effective after the US market closes on June 26, 2026.
The Russell 3000 measures about 3,000 US stocks, representing roughly 98% of the investable US equity market.
Positive
- Added to Russell 3000 Index after US market close on June 26, 2026
- Included in a benchmark covering about 3,000 US stocks and 98% of the investable US equity market
Negative
- None.
News Market Reaction – EIKN
In the Jun 26 session, EIKN gained 16.24%, reflecting a significant positive market reaction. Argus tracked a peak move of +16.6% during that session. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Board appointment | Positive | +2.9% | New independent director with extensive large‑cap corporate and board experience. |
| May 21 | ASCO abstracts | Positive | -2.2% | Six oncology abstracts made available ahead of ASCO 2026 presentations. |
| May 11 | Q1 2026 earnings | Positive | +15.9% | Strong cash position with funding runway into 2H 2027 and advancing pipeline. |
| Mar 30 | FY 2025 results | Neutral | -1.3% | Higher 2025 operating loss offset by strengthened cash after upsized IPO. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent EIKN news has often produced meaningful moves, with clinical and earnings updates drawing the strongest positive reactions while some scientific disclosures saw mixed follow-through.
Key Terms
russell 3000 index financial
russell us indexes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community
MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026.
The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The Russell 3000 Index measures the performance of approximately 3,000 stocks, designed to represent
About Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon’s initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon’s vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com.
Forward-Looking/Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential, safety, and efficacy of Eikon’s product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond; and other statements regarding Eikon’s future operations, financial performance, financial position, prospects, objectives, strategies and other future events.
These forward-looking statements are based upon management’s current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption “Risk Factors” and elsewhere in Eikon’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission (“SEC”) on May 11, 2026, and in other public filings with the SEC in the future.
As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law.
Contacts:
Investors
Alfred “Freddie” Bowie, Ph.D., CFO
ir@eikontx.com
Media
Colin Sanford
colin@bioscribe.com
